At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 29 enrolled
Drug / intervention
Everolimus (RAD001)drug
Likely dose
Everolimus (RAD001) 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Single Arm Trial to Evaluate Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of First Line Therapy With Sunitinib or Pazopanib
In Brief
A Phase 4 clinical trial evaluating Everolimus (RAD001) for Metastatic Renal Cell Carcinoma (mRCC). Completed, enrolled 29 participants across 13 sites.
Detailed Summary
Patients with metastatic renal cell carcinoma (mRCC) who failed first-line therapy with sunitinib or pazopanib was treated with everolimus. Efficacy and safety of everolimus was evaluated in these patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Renal Cell Carcinoma (mRCC)
CountriesGermany
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 2012
Enrollment StartMay 2012
Primary CompletionApr 2016
TodayJul 2026
First PostedJan 23, 2012
Enrollment StartMay 21, 2012
Primary CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 14.4 years ago
Interventions
Everolimus (RAD001)drug
Everolimus was used as commercially available formulated tablets of 10 mg strength